Search This Blog

Thursday, August 21, 2025

State senator: new evidence suggests NY’s massive $11B homecare contract was rigged

 New York lawmakers on Thursday unveiled new bombshell evidence suggesting Gov. Kathy Hochul’s administration allegedly rigged a massive contract process for an $11 billion Medicaid home healthcare program.

Aggravated state senators called the hearing in Lower Manhattan following months of controversy over the revamp of the Consumer Directed Personal Assistance Program. The lawmakers spent hours grilling Health Commissioner James McDonald and a rep for Public Partnerships LLC, the company that was awarded the no-bid contract to manage the CDPAP scheme.

State Sen. James Skoufis (D-Orange) who chairs the Committee on Investigations and Government Operations, co-chaired the testy hearing — scrutinizing whether the process to award the contract, which could prove to be a windfall for PPL, was rigged in the firm’s favor.

State Sen. Jim Skoufis is promising a follow-up after what he called “seemingly unbelievable” statements by Health Commissioner James McDonald after Thursday’s hearing.Vaughn Golden/NY Post

He confronted McDonald with a draft of state legislation from April 2024 that would have handed the contract to PPL, suggesting officials weren’t truly considering other companies. PPL eventually won the contract months later.

”There’s a bill draft from early April that names PPL. It wasn’t in the enacted version because the Senate pushed back on a no-bid contract, but the executive came to us naming PPL in a no-bid contract,” Skoufis charged.

“Then, miraculously, PPL gets the award a few months later.”

The existence of the draft bill was first noted by the Albany Times-Union in June. It reads: “The department of health, through the commissioner, shall contract with Public Partnerships, LLC (‘statewide FI’) to provide on a statewide basis the services of a fiscal intermediary.”

McDonald claimed he never saw the draft bill and maintained that the contract process was above board.

“Senator, I really don’t  know how to comment about a bill draft because I never saw that,” he said.

The governor pushed for the overhaul, ostensibly in order to cut down on rampant waste, fraud and abuse in the program, which had grown from $3 billion in 2018 to $11 billion in 2024, per McDonald’s testimony

The overhaul involves consolidating hundreds of middlemen firms that acted as “fiscal intermediaries” between Medicaid, which funds the program, and the home health aides employed by it under one company’s umbrella.

Health Commissioner James McDonald maintained he had no knowledge of the draft legislation presented by Skoufis.Vaughn Golden/NY Post

But many senators have soured on the move, after voting to approve it as part of last year’s state budget.

A PPL executive who was grilled later in the hearing claimed that the company had no contact with the governor’s office or health department prior to the contract process beginning.

“The CEO down to you, down to every other employee at the firm did not have one single phone call, email, text, any conversation prior to enactment of the budget in May?” Skoufis pressed.

“Correct,” Patty Byrnes, PPL’s vice president of government affairs said.

In a statement, Hochul’s office did not deny that it drafted the bill Skoufis presented, and maintained that the selection process for PPL was above board.

“The shift to a single fiscal intermediary went through a standard procurement process at DOH, following the law passed by the State Legislature – and no State officials knew who would be selected until the procurement process was complete,” a spokesperson for Hochul wrote in a statement.

A spokesperson for Gov. Kathy Hochul did not deny that her office drafted the version of the bill that would’ve awarded a no-bid contract for the program to PPL, months before it ultimately won a competitive bidding process that critics have alleged was rigged.Darren McGee /Office of Governor

“Now that we’ve ended the ‘wild west’ of the old system and moved to single fiscal intermediary with strong State oversight, New York can effectively protect CDPAP for home care users and workers and ensure the program delivers the best results for those who need it,” the statement said.

Several lawmakers were visibly furious with McDonald, who showed up apparently unprepared to cite specific data about the transition of hundreds of thousands of the program’s recipients and their caregivers when asked.

“I didn’t bring those numbers with me,” McDonald said, when asked by Sen. Gustavo Rivera (D-Bronx) to provide the number of workers who had been paid as of early April.

McDonald also drew jeers from the audience and more ire from lawmakers when he claimed he wasn’t aware of widely reported issues and bid rigging allegations surrounding the program.

The health commissioner repeatedly blamed “misinformation” for the agency and PPL’s failure to ensure hundreds of thousands of homecare recipients and their caregivers were transition to the new middlemen by the statutory April 1 deadline.

“I think you’re just continuing to perpetuate the misrepresentation that you claim was bestowed upon this program,” state Sen. Siela Bynoe (D-Nassau) said, excoriating the health commissioner. 

“You’re not giving us numbers. You’re not giving us data. You’re not giving anything to refute the fact that this contract was not, in fact, transitioned properly to start, and that you have any type of guidelines, protocol and a process in place to ensure that you’re maintaining what they are actually contractually required to give us,” she said.

Harlem state Sen. Cordell Cleare (D-Manhattan) told Byrnes and McDonald that their responses were “an insult” to New Yorkers.

Skoufis stopped short of calling McDonald a liar, but said his statements were “seemingly unbelievable.”

He and Rivera promised a follow up to the hearing, but did not specify if that meant subpoenaing for more information.

“A lot of the statements from both of them were stunning and seemingly unbelievable. And we’re going to continue to pursue sort of those threads,” Skoufis said.

https://nypost.com/2025/08/21/us-news/state-senator-unveils-new-evidence-suggesting-nys-massive-11b-homecare-contract-was-rigged/

Active shooter at Villanova U causes campus chaos, shelter in place order during move-in: cops

 An active shooter was reported at Villanova University on Thursday afternoon, sparking pandemonium as new students were on campus for move-in day.

Students and visitors, including many families helping their children get settled, were directed to shelter in place, according to the Radnor Township Police Department.

An alert from the university ordered everyone to stay away from the Law School Scarpa Hall, located on the West Campus near nine residence halls and a dining hall, according to a campus map

No victims have been reported, according to the RTPD. Authorities and other officials are sweeping through the buildings to help evacuate people sheltering in place.

Alarming video posted to X shows frantic students and families running for their lives and toppling over chairs during an outdoor mass that was being held to welcome the new students.

Droves of law enforcement officials were seen on campus responding to the active shooter threat.AP

A representative with the university told a group that preliminary reports indicated there may have been shots fired in the law school’s library, according to a video recorded by a person on campus.

Thursday was the first day of new student orientation, according to the university calendar.

A door with damaged glass on the Villanova campus is seen immediately after reports of an active shooter.

The law school’s orientation started on Tuesday and concluded with a picnic held with the alumni association Thursday afternoon, according to posts on X

Federal, state and local law enforcement are both on site, Pennsylvania Gov. Josh Shapiro wrote on social media.

People shelter behind a wall at the Villanova University campus where an active shooter was reported.AP

Pennsylvania Sen. Dave McCormick said that he is “aware and monitoring the situation” and “praying” for everyone on campus.

Villanova University, a private Augustinian Catholic school just 12 miles outside of Philadelphia, costs a staggering $70,000 annually for each student. 

There are roughly 1,770 students in the class of 2029, according to the university’s first-year admission profile

All students are supposed to start classes on Monday, according to the university’s academic calendar.

Earlier this afternoon, the University of Tennessee at Chattanooga was placed under lockdown after an unfounded active shooter alert. 

https://nypost.com/2025/08/21/us-news/active-shooter-at-villanova-university-causes-campus-chaos-shelter-in-place-order/

Pricey Drugs Unlikely to Solve Dementia

 Dear colleagues, I'm Christoph Diener from the faculty of medicine at the University of Duisburg-Essen, in Germany. In this month's video, I would like to concentrate on the topic of dementia. 

We made tremendous progress in the diagnosis of Alzheimer's disease, not only at a time when patients show symptoms but also in the preclinical phase of the disease.

Biomarkers and Lifestyle

We have new biomarkers in cerebrospinal fluid with amyloid and tau PET, and more recently, we have now biomarkers in plasma. One is p-tau217, and this has shown a high sensitivity for the diagnosis of Alzheimer's disease and a good correlation with cerebrospinal fluid markers, as published recently in Neurology.

A second aspect is we know that there are about 14 different lifestyle factors and comorbidities that increase the risk for mild cognitive impairment, dementia, and in particular, Alzheimer's disease. The most frequent ones — as you know — are vascular risk factors, hearing loss, smoking, high alcohol intake,obesity, and nutrition. 

Unfortunately, for most of these correlations, there have been no prospective randomized trials to show that management or treatment of these risk factors or comorbidities would really decrease the risk of Alzheimer's disease. 

Just to give you an example, there is one study from the US published in Neurologywith more than 100,000 participants, and they showed that consumption of red meat significantly increases the risk of dementia. We have in the past not really considered lifestyle factors enough to prevent Alzheimer's disease. 

Herpes Zoster and Cognitive Impairment

There are very interesting findings on the correlation between Herpes zoster and the increased risk of cognitive impairment and dementia.We have now several studies with hundreds of thousands of patients in the US, in the UK and Australia, which showed that, if someone has Herpes zoster infection, over the next 13 years, the risk of dementia is increased between 15% and 30%. 

The more interesting feature is that obviously vaccination against Herpes zoster reduces the risk of dementia.There have been several studies, including one in Wales with almost 300,000 participants. When the vaccination was introduced, participants born before 1933 were not vaccinated, while 50% of those born after 1933 were vaccinated. After 7 years, the diagnosis of dementia was reduced by 3.5% in vaccinated individuals.The relative risk reduction for dementia was 20%. 

Another aspect is which vaccine. The study from the United States with more than 100,000 people observed over 6 years showed that recombinant vaccine is more effective in preventing cognitive impairment and dementia compared to the traditional live vaccine. The risk reduction was 17%.

GLP-1 Drugs and Anti-Amyloids

We have a totally new class of medicines to treat diabetes and obesity: the GLP-1 receptor agonists. There is indirect evidence that they might also be beneficial for the prevention of dementia. One publication in JAMA Neurology looked at a database of more than 33,000 patients treated with GLP-1 receptor agonistsand 34,000 treated with SGLT2 inhibitors compared with standard therapy. 

For both substances, there was a 35%-45% reduction in the risk of Alzheimer's dementia and other dementias compared to standard therapy. This has to be shown in one of the ongoing trials with GLP-1 receptor agonists.

Let me mention the new beta-amyloid antibodies, lecanemab and donanemab. They have been approved both in the United States and in Europe for the treatment of early stages of Alzheimer's disease. This is a complicated business because you need biomarkers and amyloid PET for the diagnosis, you need regular intravenous administration, and you need MR controls to check for Amyloid-related imaging abnormalities.

At the recent Alzheimer's Congress in Toronto, for both substances, long-term data were presented for a time period of three to 4 years. They showed that with increasing time of treatment, there is also an increase, obviously, in efficacy if the data are compared with a database, not within the randomized trials, because these were open-label, long-term studies.

With donanemab, it was interesting that, in more than 75% of the patients, there was no longer amyloid detected on PET. The other important issue is that there is now a new application of donanemab that is subcutaneous. 

Spend Money on Lifestyle 

At the end of the day. I'm not really sure whether this is an effective treatment if we consider cost and risk, and I think a healthcare system would be better advised to invest all this money into teaching of at-risk persons, in particular, to have an impact on lifestyle.

I'm aware that, in low-income people, this is extremely difficult, because they cannot afford healthy food and they cannot afford to pay for a gym for regular exercise. I think we can do much better, in particular, in treating comorbidities like obesity, diabetes, hypertension, high cholesterol, and so on.

Dear colleagues, this is a short update on what has happened recently in the field of dementia. I’m Christoph Diener from the University of Duisburg-Essen Medical School. Thank you very much for listening and watching.

https://www.medscape.com/viewarticle/pricey-drugs-unlikely-solve-dementia-2025a1000lxc

Military options for Ukraine discussed by US, European national security advisers

 Military chiefs from the United States and a number of European countries on Thursday presented options to their national security advisers for providing security guarantees to Ukraine, officials said.

This followed U.S. President Donald Trump's pledge to help protect the country under any deal to end Russia's 3-1/2-year-old war in Ukraine.

A Pentagon statement said U.S. and European planners had developed the military options for "appropriate consideration" by allied national security advisers. Reuters was first to report that the military leaders were preparing the options.

The chiefs of defense for the United States, Finland, France, Germany, Italy, United Kingdom and Ukraine met in Washington, D.C., between Tuesday and Thursday.

A source familiar with the matter said U.S. Secretary of State Marco Rubio, who also serves as Trump's national security adviser, held a conference call on Thursday with his European counterparts to discuss the options.

Final details must still be worked out, the source said, but European countries would provide "the lion's share" of any forces involved in security guarantees for Ukraine.

That echoed Vice President JD Vance's comment on Wednesday that Europe would need to shoulder "the lion's share" of the costs of the operation.

"The planning work continues," said the source, adding that Washington still was "determining the scope of its role."

Trump has said he will not deploy U.S. troops in Ukraine but has left the door open to other U.S. military involvement, including air support.

TROOP DEPLOYMENTS

One option was sending European forces to Ukraine but putting the United States in charge of their command and control, sources have told Reuters.

U.S. air support could come in a variety of ways, including providing more air defense systems to Ukraine and enforcing a no-fly zone with U.S. fighter jets.

French President Emmanuel Macron and British Prime Minister Keir Starmer have both supported troop deployments as part of a coalition of the willing, with German Chancellor Friedrich Merz also signaling openness to his country's participation.

The head of Germany's soldiers' union said on Thursday that European NATO leaders must face the reality that tens of thousands of troops would need to be deployed in a Ukraine peace force for the long term.

Trump has pressed for a quick end to Europe's deadliest war in 80 years, and Kyiv and its allies have worried he could seek to force an agreement on Russia's terms.

https://www.yahoo.com/news/articles/military-options-ukraine-presented-national-143512806.html

US Adds Steel, Copper, Lithium To High-Priority List Under Uyghur Forced Labor Law

 by Aldgra Fredly via The Epoch Times (emphasis ours),

The United States will add steel, copper, lithium, and two other products to its import restriction list under the Uyghur Forced Labor Prevention Act (UFLPA), the Department of Homeland Security (DHS) announced on Aug. 19.

The U.S. Department of Homeland Security in Washington on Aug. 12, 2024. Madalina Vasiliu/The Epoch Times

DHS said it was also adding caustic soda and red dates to its high-priority list for enforcing the UFLPA, which bans the import of products made with forced labor in China’s Xinjiang region, where the Chinese Communist Party (CCP) has been committing human rights abuses against Uyghurs and other ethnic minorities, according to human rights groups and lawmakers.

“The use of slave labor is repulsive and we will hold Chinese companies accountable for abuses and eliminate threats its forced labor practices pose to our prosperity,” DHS Secretary Kristi Noem said in a statement.

At present, there are 144 entities on the UFLPA Entity List that have been accused of using the forced labor of Uyghurs and other ethnic minorities in the Xinjiang region, according to the statement.

DHS stated that as of Aug. 1, U.S. Customs and Border Protection (CBP) had blocked more than 16,700 imported shipments valued at nearly $3.7 billion to examine whether they are prohibited under the UFLPA, and more than 10,000 of the shipments were denied entry.

“America has a moral, economic, and national security duty to eradicate threats that endanger our nation’s prosperity, including unfair trade practices that disadvantage the American people and stifle our economic growth,” Noem stated. “The Trump administration is taking action.”

The department also released its update to the UFLPA enforcement strategy, underscoring the Trump administration’s efforts to block Chinese goods made with forced labor from entering the United States.

According to the strategy report, the Forced Labor Enforcement Task Force listed high-priority sectors to provide importers with transparency and allow businesses to scrutinize supply chains involving products in those sectors.

“Ending forced labor is an economic and national security imperative for the United States,” Christopher Pratt, a senior DHS official performing the duties of the undersecretary for strategy, policy, and plans, stated in the report.

Pratt said that cracking down on imports made with forced labor helps protect compliant U.S. and international manufacturers from unfair competition while also promoting U.S. businesses and industries.

Under the UFLPA, businesses are banned from importing products produced wholly or in part in Xinjiang, unless they can provide “clear and convincing evidence” that no forced labor was used in producing the imported goods, according to the DHS website.

The United States has described the detention of more than 1 million Uyghur and other Muslim minorities in Xinjiang as a genocide, and both the first Trump administration and the Biden administration imposed sanctions on Chinese officials for suppression in Xinjiang.

In March, the State Department imposed visa restrictions on current and former Thai officials involved in the deportation of 40 Uyghurs from Thailand to China on Feb. 27.

Eva Fu and Dorothy Li contributed to this report.

https://www.zerohedge.com/markets/us-adds-steel-copper-lithium-high-priority-list-under-uyghur-forced-labor-law

Krystal Biotech adjusts pipeline to prioritize inhaled antitumor agent

 Krystal Biotech (NASDAQ:KRYS) announced Thursday a revamped product pipeline after a decision to prioritize studies for an inhaled version of its antitumor candidate KB707 targeted at non-small cell lung cancer.

The decision followed an End of Phase 2 meeting granted by the FDA to discuss the registrational path for inhaled KB707 based on the immunotherapy's early efficacy results, Krystal Biotech (NASDAQ:KRYS) said.

As a result, the Pittsburgh, Pennsylvania-headquartered biotech will pause enrollment in its OPAL-1 Phase 1/2 open-label trial designed to evaluate intratumoral KB707 in patients with solid tumors.

However, enrollment in its KYANITE-1 Phase 1/2 trial, which evaluates inhaled KB707 in solid tumors of the lung, will continue.

The company added that it will further revise R&D plans for intratumoral KB707 based on safety and efficacy data from OPAL-1, as patients in that study will continue to be monitored.

https://www.msn.com/en-us/money/savingandinvesting/krystal-biotech-adjusts-pipeline-to-prioritize-inhaled-antitumor-agent/ar-AA1KYeO7